common.study.topics.clinical

BONEBRIDGE Bone Conduction Implant in Adults

common.study.values.description

“BONEBRIDGE Bone Conduction Implant in Adults”

Approximately thirty subjects with mixed or conductive hearing loss, meeting FDAa??cleared candidacy criteria for the BONEBRIDGE, will be implanted and followed for three (3) months posta??activation to assess safety and effectiveness of the BONEBRIDGE implant.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Recruiting patients only common.study.methods.is-healthy-yes

Device - BONEBRIDGE

Bone Conduction Implant

participant.views.study.view.additional

participant.views.study.view.scientific-title

Outcomes in Adults With Mixed or Conductive Hearing Loss Implanted With the BONEBRIDGE

common.study.values.clinical-trial-id

NCT03859648

participant.views.study.view.id

eZ6G2e